Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC (RETRO-ROC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02394015
Recruitment Status : Completed
First Posted : March 20, 2015
Last Update Posted : March 27, 2020
Sponsor:
Collaborator:
PharmaMar
Information provided by (Responsible Party):
Grupo Español de Investigación en Cáncer de Ovario

Brief Summary:
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.

Condition or disease Intervention/treatment
Ovarian Epithelial Cancer Recurrent Drug: Trabectedin and Pegylated Liposomal Doxorubicin

Layout table for study information
Study Type : Observational
Actual Enrollment : 90 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet
Actual Study Start Date : May 6, 2013
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017


Group/Cohort Intervention/treatment
Trabectedin+ PLD
Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
Drug: Trabectedin and Pegylated Liposomal Doxorubicin
Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014




Primary Outcome Measures :
  1. Efficacy progression-free survival (PFS) [ Time Frame: Up to 12 months ]
    Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of progression-free survival ( PFS).

  2. Overall survival (OS) [ Time Frame: Up to 12 months ]
    Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of overall survival (OS ) .


Secondary Outcome Measures :
  1. Response rate to previous and post-treatment (Percentage of responses (CR+PR) [ Time Frame: Up to 12 months ]
    Percentage of responses (CR+PR) at pretreatment and post-treatment

  2. Response rate to trabectedin - DLP combination (Percentage of responses (CR+PR) [ Time Frame: Up to 12 months ]
    Percentage of responses ( CR + PR ) to trabectedin - DLP

  3. Clinical Benefit in 4 months (Percentage of clinical benefit (CR + PR + SD) [ Time Frame: Up to 12 months ]
    Percentage of clinical benefit (CR + PR + SD for at least 4 months)

  4. Impact of trabectedin - PLD combination in subsequent treatments [ Time Frame: Up to 12 months ]
    Assessment of the impact of treatment with trabectedin - PLD combination at the beginning of subsequent treatments

  5. Toxicity (adverse events) [ Time Frame: Up to 12 months ]
    type , incidence , severity, frequency, severity and relationship to the treatment of adverse events reported in patients reports

  6. Comparison between PFS and PFS2 [ Time Frame: Up to 12 months ]
    Comparison of the PFS of prior platinum combination TRB + DLP and subsequent platinum PFS.

  7. Hypersensitivity and allergic reactions (Number and Management of hypersensitivity reactions or allergies) [ Time Frame: Up to 12 months ]
    Number and Management of hypersensitivity reactions or allergies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have received treatment with trabectedin - DLP for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been included in clinical trials where the IMP was trabectedin.
Criteria

Inclusion Criteria:

  • Patients who have received at least one dose of trabectedin - doxorubicin pegylated for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been included in clinical trials where the IMP was trabectedin.

Exclusion Criteria:

  • Patients with records unavailable (lost, empty or not recoverable).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02394015


Sponsors and Collaborators
Grupo Español de Investigación en Cáncer de Ovario
PharmaMar
Investigators
Layout table for investigator information
Principal Investigator: Laura Vidal, MD H. Clinic, Barcelona
Principal Investigator: Jose M Del Campo, MD H. Vall d'Hebron, Barcelona
Layout table for additonal information
Responsible Party: Grupo Español de Investigación en Cáncer de Ovario
ClinicalTrials.gov Identifier: NCT02394015    
Other Study ID Numbers: GEICO 1402R
GEI-TRAB-2014-01 ( Other Identifier: AEMPS )
First Posted: March 20, 2015    Key Record Dates
Last Update Posted: March 27, 2020
Last Verified: March 2020
Keywords provided by Grupo Español de Investigación en Cáncer de Ovario:
Platinum-sensitive Recurrent Ovarian Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Hypersensitivity
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immune System Diseases
Doxorubicin
Liposomal doxorubicin
Trabectedin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents